Description
The abstract identifies ADAM10 as having a wide variety of substrates beyond amyloid precursor protein, including collagen IV and TNF-α, but states that side effects of therapeutic enhancement must be considered without detailing what these are. This knowledge gap is critical for safe therapeutic development targeting ADAM10 upregulation in Alzheimer’s disease.
Gap type: open_question Source paper: Upregulation of the alpha-secretase ADAM10–risk or reason for hope? (2010, The FEBS journal, PMID:20136654)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:27.188073+00:00”, “resolution_summary”: “Resolved by hypothesis h-trem2-fe8c644a: Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Inflammation. Supporting evidence includes debate sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-trem2-fe8c644a”, “title”: “Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Inflammation”, “score”: 0.227, “reason”: “18 token overlaps; entity overlap: adam10”, “analysis_id”: “SDA-2026-04-02-gap-001”, “target_gene”: “TREM2, ADAM10, ADAM17”, “target_pathway”: “ectodomain shedding, microglial survival signaling”, “disease”: “Alzheimer’s disease”, “composite_score”: 0.71429, “confidence_score”: 0.65, “status”: “proposed”, “pubmed_evidence_ids”: [“27986010”, “29695715”, “33483491”, “41509917”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.468, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d”, “title”: “The abstract explicitly questions whether AD’s hallmark pathologies induce cholinergic dysfunction or vice versa. This fundamental causality question is critical for determining therapeutic targets but remains unresolved despite evidence that β-amyloid affects cholinergic receptors.\n\nGap type: open_question\nSource paper: The cholinergic system in aging and neuronal degeneration. (2011, Behavioural brain research, PMID:21145918)”, “score”: 0.4, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-20260411-082446-2c1c9e2d_20260412-210950”, “title”: “The abstract explicitly questions whether AD’s hallmark pathologies induce cholinergic dysfunction or vice versa. This fundamental causality question is critical for determining therapeutic targets but remains unresolved despite evidence that β-amyloid affects cholinergic receptors.\n\nGap type: open_question\nSource paper: The cholinergic system in aging and neuronal degeneration. (2011, Behavioural brain research, PMID:21145918)”, “score”: 0.4, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-20260411-082446-2c1c9e2d”, “quality_score”: 0.79, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.395, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.395, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}